BridgeMD
New treatment option for Biliary Tract Cancer (BTC)
Official title HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
ClinicalTrials.gov ID: NCT07466238
What this study is testing
What is Bevacizumab?
Bevacizumab is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for biliary tract cancer (btc).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Biliary tract cancer (BTC), including cholangiocarcinoma and gallbladder cancer (GBC), is a group of malignancies with highly heterogeneous, highly aggressiveness, and poor prognosis. Surgery is recognized as the only curative treatment for BTC, however, only about 20% BTC patients are eligible for curative resection since most patients with BTC are diagnosed at an advanced stage.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Age: 18-80 years, both genders.
- Diagnosis of biliary tract cancer (including intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, and gallbladder cancer) and confirmed by...
- Without distant metastasis or limited distant metastasis
- Treatment-naive.
- ECOG PS score \< 2.
You likely can't join if
- Coexistent or synchronous malignancies.
- Distal cholangiocarcinoma.
- Allergic to contrast agents or oxaliplatin.
- Pregnant or lactating women.
- Multiple extrahepatic metastases or combined malignant pleural and peritoneal effusions.
- History of organ transplantation.
See the full eligibility criteria
- Age: 18-80 years, both genders.
- Diagnosis of biliary tract cancer (including intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, and gallbladder cancer) and confirmed by histopathological or cytopathological examination.
- Without distant metastasis or limited distant metastasis
- Treatment-naive.
- ECOG PS score \< 2.
- Child-Pugh score: Class A or B (≤7).
- Normal major organ function, meeting the following standards:(1) Blood routine examination:A. Hb≥90 g/L;B. ANC≥1.5×10\^9/L;C. PLT≥75×10\^9/L;(2) Biochemical examination:A. ALB ≥30g/L;B. ALT and AST\<5×ULN;C. TBiL...
- Coexistent or synchronous malignancies.
- Distal cholangiocarcinoma.
- Allergic to contrast agents or oxaliplatin.
- Pregnant or lactating women.
- Multiple extrahepatic metastases or combined malignant pleural and peritoneal effusions.
- History of organ transplantation.
- With infections requiring anti-infection treatment.
- Severe and irreparable coagulation dysfunction.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.